Sevoflurane Protects Rat Heart Cells from Oxygen Injury Through an RNA Regulatory Axis

Sevoflurane, an inhaled anesthetic long suspected of shielding heart tissue from stress, has now been linked to a specific molecular circuit in laboratory-grown rat heart cells. A new open-access study published in Cell Biology and Toxicology reports that the gas eased injury in cardiomyocytes subjected to hypoxia followed by reoxygenation by acting on a regulatory pathway involving the long non-coding RNA LINC00173, the microRNA miR-490-3p, and the signaling gene MAPK1.

The research team, led by Li Zhang and Li Liu, worked with H9c2 rat cardiomyocytes, a widely used cell line in cardiac injury research. The cells were exposed to hypoxia and reoxygenation, a laboratory protocol that mimics the damage heart tissue suffers when blood supply is cut off and then restored, as happens during ischemia-reperfusion injury. Sevoflurane was applied as a post-conditioning treatment after the hypoxic episode.

To map what changed, the investigators combined quantitative real-time PCR to measure gene expression, CCK-8 assays to track cell viability, ELISA to quantify inflammatory cytokines and injury markers, and Western blotting to assess oxidative stress indicators and apoptosis-related proteins. Dual-luciferase reporter assays were used to verify whether the proposed molecular targeting relationships were direct.

The results showed a clear pattern. Hypoxia/reoxygenation injury significantly increased expression of LINC00173 and MAPK1 while suppressing miR-490-3p. Sevoflurane post-conditioning reversed all three changes, restoring the expression profile toward normal levels.

The reporter assays confirmed two direct interactions at the heart of the proposed mechanism: LINC00173 binds miR-490-3p, and miR-490-3p in turn targets MAPK1. This arrangement fits a well-known lncRNA architecture in which a long non-coding RNA acts as a molecular sponge, soaking up a microRNA and preventing it from restraining its downstream target gene.

Functional experiments then tested whether the axis actually drives the protective effect. When the researchers overexpressed LINC00173, the benefit of sevoflurane on cell viability was partially reversed, and the cells showed worse injury and more apoptosis. Overexpressing miR-490-3p counteracted these detrimental effects, suggesting the microRNA is the functional intermediary through which LINC00173 acts.

The third node completed the picture. Knocking down MAPK1 significantly reversed the cell damage caused by inhibiting miR-490-3p, placing MAPK1 downstream in the pathway. Taken together, the authors conclude that sevoflurane downregulates LINC00173, which relieves the sponge-mediated inhibition of miR-490-3p, allowing the microRNA to suppress MAPK1 expression and thereby reduce injury and apoptosis.

The study’s scope deserves careful emphasis. All findings come from a rat cardiomyocyte cell line under controlled laboratory conditions, not from living animals or patients. H9c2 cells, while standard for this kind of work, do not fully reproduce adult human heart muscle, and hypoxia/reoxygenation in a dish is only an approximation of clinical ischemia-reperfusion. The authors frame the axis as a potential novel target for sevoflurane against myocardial ischemia-reperfusion injury, a hypothesis that would require validation in animal models and eventually clinical settings.

Even so, the work adds to a growing family of studies identifying sevoflurane-responsive lncRNA/microRNA axes in cardiac cells, including reported pathways involving LINC01278/miR-134-5p, FAM201A/miR-488-3p/PTEN, and LINC00265/miR-370-3p. The consistent theme is that the anesthetic’s apparent cardioprotective effects may operate through competing endogenous RNA networks rather than a single protein target.

For now, the practical takeaway is mechanistic rather than medical: sevoflurane’s protection of stressed heart cells in this model was traced to a specific, experimentally verified RNA regulatory circuit. Whether manipulating LINC00173, miR-490-3p, or MAPK1 could ever translate into therapies for patients undergoing cardiac surgery or heart attack reperfusion remains an open question that this cell-line study alone cannot answer.

Subject of Research: Sevoflurane's protection of hypoxia/reoxygenation-injured rat cardiomyocytes through the LINC00173/miR-490-3p/MAPK1 regulatory axis

Article Title: Sevoflurane alleviates hypoxia/reoxygenation-induced cardiomyocyte injury via the LINC00173/miR-490-3p/MAPK1 axis

Article References: Zhang, L., & Liu, L. (2026). Sevoflurane alleviates hypoxia/reoxygenation-induced cardiomyocyte injury via the LINC00173/miR-490-3p/MAPK1 axis. Cell Biology and Toxicology. https://doi.org/10.1007/s10565-026-10291-z

Image Credits: AI Generated

DOI: 10.1007/s10565-026-10291-z

Keywords: sevoflurane, cardiomyocytes, hypoxia/reoxygenation, LINC00173, miR-490-3p, MAPK1, long non-coding RNA, ischemia-reperfusion injury, H9c2 cells, apoptosis, lncRNA sponge mechanism, Cell Biology and Toxicology